Brian Abrahams analyst RBC

Currently out of the existing stock ratings of Brian Abrahams, 290 are a HOLD (40%), 430 are a BUY (59.31%), 5 are a SELL (0.69%).

Brian Abrahams

Work Performance Price Targets & Ratings Chart

Analyst Brian Abrahams, currently employed at RBC, carries an average stock price target met ratio of 46.4% that have a potential upside of 33.62% achieved within 218 days.

Brian Abrahams’s has documented 1,398 price targets and ratings displayed on 42 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 27-Feb-2025.

Wall Street Analyst Brian Abrahams

Analyst best performing recommendations are on CNST (CONSTELLATION PHARMACEUTICALS).
The best stock recommendation documented was for CNST (CONSTELLATION PHARMACEUTICALS) at 10/10/2019. The price target of $20 was fulfilled within 27 days with a profit of $11.9 (146.91%) receiving and performance score of 54.41.

Average potential price target upside

ATAI ATAI Life Sciences BV BIIB Biogen CELG Celgene DVAX Dynavax Technologies ENTA Enanta Pharmaceuticals ETN Eaton PLC GILD Gilead Sciences GLPG Galapagos NV ADR HOOK Hookipa Pharma ICPT Intercept Pharmaceuticals INCY yte ITCI Intracellular Th KPTI Karyopharm Therapeutics KRTX Karuna Therapeutics MRUS Merus BV NBIX Neurocrine Biosciences OVID Ovid Therapeutics PLRX Pliant Therapeutics  PTCT PTC Therapeutics SAGE Sage Therapeutic SRPT Sarepta Therapeutics VRTX Vertex Pharmaceuticals CNST Constellation Pharmaceuticals IGMS IGM Biosciences BCRX BioCryst Pharmaceuticals ALDR Alder BioPharmaceuticals MRNS Marinus Pharmaceuticals MTCR Metacrine  XENE Xenon Pharmaceuticals ETNB 89bio PRTA Prothena plc REGN Regeneron Pharmaceuticals NBSE NeuBase Therapeutics ACHN Achillion Pharmaceuticals CRBP Corbus Pharmaceuticals EIGR Eiger Biopharmaceuticals ITMN InterMune MNMD Mind Medicine  MRTX Mirati Ther PTI Proteostasis Therapeutics AMAM Ambrx Biopharma American Depositary Shares AXSM Axsome Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

1 months 2 days ago
(29-Jan-2025)

0/2 (0%)

$38.83 (347.63%)

Buy

3 months 13 days ago
(18-Nov-2024)

0/2 (0%)

$16.83 (150.67%)

Buy

8 months 10 days ago
(21-Jun-2024)

0/1 (0%)

$26.23 (139.74%)

Buy

$9

$7.28 (423.26%)

1 years 9 months 19 days ago
(12-May-2023)

0/3 (0%)

$7.1 (373.68%)

Buy

1 years 11 months 4 days ago
(27-Mar-2023)

0/1 (0%)

$17.08 (114.48%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Brian Abrahams is most bullish on?

Potential upside of $485.26 has been obtained for REGN (REGENERON PHARMACEUTICALS)

Which stock is Brian Abrahams is most reserved on?

Potential downside of -$71.79 has been obtained for VRTX (VERTEX PHARMACEUTICALS)

What Year was the first public recommendation made by Brian Abrahams?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?